


PRODUCT INFORMATION



Piroxicam

Item No. 13368

CAS Registry No.: 36322-90-4
Formal Name: 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
Synonym: NSC 666076
MF: C₁₅H₁₃N₃O₄S
FW: 331.4
Purity: ≥95%
UV/Vis.: λ_{max}: 206, 240, 330 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Piroxicam is supplied as a crystalline solid. A stock solution may be made by dissolving the piroxicam in the solvent of choice, which should be purged with an inert gas. Piroxicam is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of piroxicam in these solvents is approximately 20 mg/ml.

Piroxicam is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, piroxicam should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Piroxicam has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Piroxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties.^{1,2} It inhibits production of thromboxane B₂ (TXB₂; Item No. 19030) from arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) in HEL human erythroleukemic cells (IC₅₀ = 0.45 μM), which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F_{1α} (PGF_{1α}; Item No. 15010) from arachidonic acid in Mono-Mac-6 cells (IC₅₀ = 0.77 μM), which endogenously express COX-2.² Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC₅₀ values of 240 and ~470 μM, respectively. It reduces carrageenan-induced paw edema in rats when administered at doses of 1, 2.5, and 5 mg/kg.³ Formulations containing piroxicam have been used in the treatment of pain and inflammation associated with osteoarthritis and rheumatoid arthritis.

References

1. Pairet, M., van Ryn, J., Schierok, H., *et al.* Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer. *Inflamm. Res.* **47(6)**, 270-276 (1998).
2. Berg, J., Fellier, H., Christoph, T., *et al.* The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 *in vitro*. *Inflamm. Res.* **48(7)**, 369-379 (1999).
3. Buritova, J., Honore, P., Chapman, V., *et al.* Carrageenan oedema and spinal Fos-LI neurones are reduced by piroxicam in the rat. *Neuroreport* **6(10)**, 1385-1388 (1995).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/02/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM